Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...

The classification of AML and therapeutic options are now largely driven by genetically defined subtypes. Personalization of treatment relies on timely completion and reporting of cytogenetic and ...

LabPMM ®, an Invivoscribe ® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is ...

A highly sensitive bone marrow test could double survival rates for some groups of younger adults with acute myeloid leukemia (AML) by helping doctors identify if they might relapse up to three months ...

A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research (NIHR) ...